Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TA4N
|
|||
| Drug Name |
PMID28394193-Compound-13
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
EPIZYME, INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H39N7O2
|
|||
| Canonical SMILES |
CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(N(NC5=O)CC)C)C
|
|||
| InChI |
1S/C30H39N7O2/c1-6-20(4)36-18-19(3)28-24(29(38)33-17-25-21(5)37(7-2)34-30(25)39)14-23(15-26(28)36)22-8-9-27(32-16-22)35-12-10-31-11-13-35/h8-9,14-16,18,20,31H,6-7,10-13,17H2,1-5H3,(H,33,38)(H,34,39)
|
|||
| InChIKey |
MQDSSXUQHUNJLJ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Enhancer of zeste homolog 2 (EZH2) | Target Info | Inhibitor | [1] |
| EZH2 Y641F mutant (EZH2 Y641F) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Enhancer of zeste homolog 2 (EZH2) | Target's Patent Info | [1] | |
| EZH2 Y641F mutant (EZH2 Y641F) | Target's Patent Info | [1] | ||
| KEGG Pathway | MicroRNAs in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | PRC2 methylates histones and DNA | |||
| Oxidative Stress Induced Senescence | ||||
| PKMTs methylate histone lysines | ||||
| WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | |||
| Endoderm Differentiation | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Histone Modifications | ||||
| Cell Differentiation - meta | ||||
| miRs in Muscle Cell Differentiation | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.